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EDITORIAL COMMENT
Genetic Pleiotropy in Depression and Coronary Artery Disease
Strong evidence has accrued over the past decade that depressive
symptoms predict future cardiac disease (1,2). The link is not
“merely” significant; the effect size is sufficiently high to suggest
that it is also relevant. Depression is estimated to confer a relative
risk between 1.5 and 2.0 for the onset of coronary artery disease
(CAD) in healthy individuals, whereas depression in patients
with existing CAD confers a relative risk between 1.5 and 2.5 for
new morbidity and mortality (3). Here we had a link between
psychosocial factors and somatic disease that could not be easily
silenced by hard-core “psychosomatic medicine skeptics” (4). So
we thought. Then things started to go awry. A large randomized
controlled trial that targeted depressive symptoms and social
isolation by behavioral therapy (ENRICHD) did not reduce the
risk for myocardial reinfarction or mortality (5). This was bad
news. First and foremost for those afflicted with CAD, be-
cause a novel therapeutic route to supplement usual care
appeared to be shut off. The news was also bad for the field:
strong prospective evidence for a link between psyche and
soma will not necessarily materialize as a causal effect.
Explanations for the disappointing results abound (6), and
secondary analyses may yet change our overall perception of
this trial (7,8). In this issue of Psychosomatic Medicine, Mc-
Caffery and colleagues (9) urge us to be willing to entertain an
alternative explanation for the current state of affairs. We need
to remind ourselves that prediction is nothing more than an
association, in this case an association of a trait (depression) at
wave 1 with another trait (coronary artery disease) at wave 2
of data collection. Remember that association does not equate
with causation? Individual differences in some underlying
dimension could affect susceptibility for depression at time 1
but simultaneously, and unrelated to its effects on depression,
also affect the severity of CAD at time 2. This would give rise
to a prospective link between depressive symptoms and CAD,
but causal effects would flow forth from the underlying di-
mension only. McCaffery and colleagues propose that this
underlying dimension is in part to be found in individual
differences in genetic makeup.
The crucial concept is that of genetic pleiotropy, i.e., the
finding that a single gene can influence variance in multiple
and very diverse traits. For instance, variation in the gene
coding for the 5-HT2A receptor might influence the ease by
which the receptor is incorporated into the cell membrane. In
the central nervous system, the increased receptor density may
affect serotonergic neurotransmission and influence mood
regulation. In peripheral tissues, the increased receptor density
may enhance platelet aggregation and vasoconstriction. These
central and peripheral effects of the 5-HT2A gene may be
completely unconnected; they may just reflect the evolution-
ary mechanism that nature selects for a successful ligand-
receptor system and re-employs whenever it sees fit.
The existence of genetic pleiotropy can be demonstrated by
a twin study. Twins come in two flavors: monozygotic twins,
who are genetically identical; and dizygotic twins, who share
on average 50% of their genetic material (10). The crucial
piece of information needed to detect pleiotropy is found in
the cross-twin cross-trait correlations. If the depressive symp-
toms of a twin predict CAD in their co-twin, this can only be
explained by an underlying factor that affects both depression
and CAD and is shared by members of a family. If the
prediction is about twice as strong in monozygotic twins than
in dizygotic twins, this signals that the underlying factor is
their shared genetic makeup. Exactly this result has been
found (11), and 17% of variability in depressive symptoms
and self-reported heart disease appears to be attributable to
common genetic factors influencing both traits.
In twin studies, these genetic factors remain anonymous
(the latent “G” factors in the often-used path diagrams); but
when DNA has been collected, actual genes can be tested
using genetic association analysis. McCaffery and colleagues
review the current molecular genetic evidence for pleiotropy
as a potential source of the association between CAD and
depressive symptoms (10). In selecting genes, the authors
have focused on inflammation and serotonergic cell-to-cell
signaling as two potential pathways that could influence both
affective state and cardiovascular functioning. A comprehen-
sive list of candidate genes in these pathways is discussed,
although by necessity constrained by our current knowledge
of the human genome. From the listed candidate genes, the
most convincing case is made for TNFA, IL1B, 5-HTT,
5-HT2A, and 5-HT2B because polymorphic variation within
these genes has already been linked to both depression and
CAD.
Taking the concept of pleiotropy to the extreme could mean
that actively changing psychosocial risk would have little pre-
ventive value at all, since it would not change the subject’s
genotype. This is hard to digest. In defense of true causal effects
driving the prospective link between depression and CAD out-
come, one should point out that evidence for pleiotropy still does
not exclude additional causal effects. All that is shown, by the
reviewed twin and association studies alike, is that some genes
may influence variance in both traits. This can mean one of four
things: genes cause depression and depression causes CAD,
genes cause CAD and CAD causes depression, genes cause
depression and CAD but do so independently (true pleiotropy).
Finally, in a fourth and most likely scenario, the previous three
scenarios coexist. Some genes for CAD may act by causing
Address correspondence and reprint requests to Eco J. C. de Geus, PhD,
Department of Biological Psychology, Vrije Universiteit, van der Boechorst-
straat 1, Amsterdam, NH 1081 BT Netherlands. E-mail: eco@psy.vu.nl
DOI: 10.1097/01.psy.0000208628.90274.bc
185Psychosomatic Medicine 68:185–186 (2006)
0033-3174/06/6802-0185
Copyright © 2006 by the American Psychosomatic Society
depressive symptomatology (e.g., 5-HTT (12) or FKBP5 (13))
and through the chronic stress of depression worsen CAD
prognosis (14); some genes may act directly on atherosclerosis
(e.g., IL1B (15,16)) and the resulting vascular disease may
influence the course of depression (17); still other genes may
act to affect mood in the central nervous system but indepen-
dently act on CHD risk in peripheral tissues like the heart and
blood vessels (e.g., genes coding for adrenoceptors). All this is
hypothetical, of course, but the important message conveyed
by the review is that we can and should test such hypotheses.
I found the review to be exemplary in three ways. First, a
series of candidate genes are listed that allow empirical inter-
rogation of the new theoretical position that genetic pleiotropy
may explain part of the link between depressive symptoms
and CAD. Second, the paper was co-authored by pioneers in
the depression/CAD link, who now dare question their previ-
ous conclusions. This open-mindedness refutes the sentiment
that this field is unwilling to change theory when faced with
unfavorable empirical evidence. Third, and most importantly,
the review by McCaffery and colleagues shows that research-
ers with a firm base in psychosomatic medicine can success-
fully adopt genetic strategies and, most importantly, become
beneficiaries of the Human Genome Project. DNA is just
another tool to help us chart the pathways connecting body
and mind. If we consider psychosomatic medicine to be a
complex puzzle, then genes should simply be regarded as the
edge pieces.
The edges are generally not a bad place to start assembling
a puzzle.
ECO J. C. DE GEUS, PHD
From the Department of Biological Psychology &
the Netherlands Twin Registry, Vrije Universiteit,
Amsterdam, The Netherlands.
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